Integer (ITGR)
Develops and manufactures cardiac, vascular, and neuromodulation devices for medical-technology companies.
Something off on this page? Send us feedback.
Develops and manufactures components, subassemblies, and finished devices for cardiac, vascular, and neuromodulation programs. Revenue comes largely from custom work for large medical-device OEMs, with roughly half tied to Abbott, Boston Scientific, and Medtronic.
Develops and manufactures medical-device components, subassemblies, and finished systems across three product lines: Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets. The portfolio spans catheters, guidewires, delivery systems, implantable batteries, capacitors, feedthroughs, leads, pulse generators, precision machining, and proprietary surface coatings.
Runs a manufacturing network across the United States, Mexico, Ireland, and several other countries, pairing customer-specific engineering with scaled production. Large medical-device OEMs contract most work to their specifications; Abbott, Boston Scientific, and Medtronic together account for roughly half of sales.
Programs depend on qualified suppliers, validated quality systems, and regulatory approvals, while finished-device facilities remain subject to FDA and international oversight. A pending KKR acquisition would take the shares private, subject to stockholder and regulatory approvals.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 14, 2026 | Benchmark | Downgrade | ||
| Aug 13, 2026 | Benchmark | Downgrade | ||
| Aug 4, 2026 | Truist Securities | Downgrade | ||
| Aug 4, 2026 | Freedom Capital Markets | Downgrade | ||
| Aug 4, 2026 | Oppenheimer | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jul 3, 2026Cash & short-term investments $21.4M · Total debt $1.36B · Total assets $3.42B · Shareholders' equity $1.72B
- Revenue
- $464.1M
- Operating income
- $34.5M
- Net income
- $23.6M
No dividends on record.
| Institutions | 121.30% | 41.23M shares | |
|---|---|---|---|
| 337 holders · as of Jun 30, 2026 | |||
| Insiders | 1.01% | 342.3K shares | |
| 23 holders · as of Sep 16, 2026 | |||
| Adds to | 122.31% | ||
33.99M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 122.31%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 15.75% | 5.35M | as of Jun 30, 2026 |
Invesco Ltd.Institution | 6.61% | 2.25M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 6.00% | 2.04M | as of Jun 30, 2026 |
Dimensional Fund Advisors LPInstitution | 4.79% | 1.63M | as of Jun 30, 2026 |
Nomura Holdings IncInstitution | 4.57% | 1.55M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 15, 2026 | Kirk K. Thor | officer: Chief Human Resources Officer | −11,767 | $126.23 |
| Sep 14, 2026 | Kirk K. Thor | officer: Chief Human Resources Officer | −19,773 | $126.25 |
| Sep 8, 2026 | Andrew Senn | officer: President, Growth & Innovation | −9,408 | $126.30 |
| Mar 13, 2026 | Tommy P. Thomas | officer: VP, Corporate Controller | −825 | $85.00 |
| Nov 11, 2025 | Tommy P. Thomas | officer: VP, Corporate Controller | −884 | $70.15 |
- TE Connectivity
Catheter, Nitinol, and polymer tubing competitor for interventional OEMs
- Jabil
Largest healthcare contract manufacturer with expanding catheter and EP programs
- Nordson
Proprietary catheter components supplier to the same interventional OEM base
- Flex
$2.6B Health Solutions contract manufacturer serving cardiac and neural OEMs
- Plexus
Full-device EMS CDMO serving cardiac and life sciences OEMs
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Integer | $126.33 | −0.04% | $4.29B | 34.5 | 19.0 | 2.3 | −2.6% |
| TE Connectivity | $213.48 | 0.00% | $60.89B | 20.6 | 17.0 | 3.2 | +13.8% |
| Jabil | $308.98 | +0.03% | $31.82B | 37.9 | 19.6 | 0.9 | +11.8% |
| Nordson | $319.67 | +0.02% | $17.51B | 31.8 | 25.3 | 5.9 | +10.3% |
| Flex | $113.99 | −0.45% | $41.23B | 43.1 | 22.0 | 1.4 | +20.6% |
| Plexus | $263.33 | −0.08% | $6.75B | 37.3 | 26.3 | 1.5 | +28.1% |
| Median | 37.3 | 22.0 | 1.5 | +13.8% |